-cyclopentyladenosine (CCPA, A1AR selective), 2-(2-carboxyethyl)phenethyl amino-5Ј-N-ethylcarboxamido-adenosine (CGS-21680, A2A selective), and 2-chloro-N 6 -3-iodobenzyladenosine-5Ј-Nmethyluronamide (Cl-IBMECA, A3 selective) were obtained to determine relaxation. Adenosine and NECA (0.1 M) caused small contractions of 13.9 Ϯ 3.0 and 16.4 Ϯ 6.4%, respectively, and CCPA at 0.1 and 1.0 M caused contractions of 30.8 Ϯ 4.3 and 28.1 Ϯ 3.9%, respectively, in A1AR (ϩ/ϩ) rings. NECA-and CCPA-induced contractions were eliminated by 100 nM of 1,3-dipropyl-8-cyclopentylxanthine (DPCPX, selective A1AR antagonist). Adenosine, NECA, and CGS-21680 produced an increase in maximal relaxation in A1AR (Ϫ/Ϫ) compared with A1AR (ϩ/ϩ) rings, whereas Cl-IBMECA did not produce contraction in either A1AR
(ϩ/ϩ) or A1AR (Ϫ/Ϫ) rings. CCPA-induced contraction at 1.0 M was eliminated by the PLC inhibitor U-73122. These data suggest that activation of A1ARs causes contraction of vascular smooth muscle through PLC pathways and negatively modulates the vascular relaxation mediated by other adenosine receptor subtypes.
A1 adenosine receptor; knockout mice; smooth muscle; ADENOSINE IS AN IMPORTANT regulator of vascular tone. Responses to adenosine are mediated via activation of four receptor subtypes, namely, A 1 , A 2A , A 2B , and A 3 adenosine receptors, and the vascular effects vary with regard to the circulation and receptor subtype of interest. In the coronary vasculature, adenosine causes vasodilation primarily through activation of A 2A receptors (1, 3, 6, 7, 14, 15, 23) . However, at least in mice, there appears to be modification of this response through activation of A 2B and/or A 3 receptor subtypes (8, 14, 22, 23) . Adenosine-induced aortic relaxation is predominantly mediated via A 2B adenosine receptor activation in mice (23) , but it is unclear whether other adenosine receptor subtypes modulate the vascular response. This possibility is supported by the observation that A 1 receptors are coexpressed with the other adenosine receptor subtypes in both the coronary and aortic vascular beds (6, 7, 9, 10, 18 -20) .
Earlier evidence indirectly suggests that the adenosine A 1 receptor negatively modulates the effect of adenosine on vascular tone (9, 10) . The selective A 1 receptor agonist 2S-N 6 -2-endo-norbornyl (S-ENBA) induced contraction in theophylline (a nonselective adenosine receptor blocker)-treated compared with nontreated aortic rings. This effect was explained as the consequence of an upregulation of A 1 adenosine receptors due to theophylline treatment (9) . Selective activation of adenosine A 1 receptors by S-ENBA also significantly attenuated the relaxation mediated by isoproterenol and inhibited basal and isoproterenol-stimulated cAMP accumulation in porcine coronary rings (10) . Treatments with the A 1 receptor antagonist 1,3-dipropyl-8-cyclopentylxanthine (DPCPX) or pertussis toxin antagonized this inhibitory effect (10) . These findings together indirectly suggest that A 1 receptors may play a role in modulating vascular function by attenuating relaxation. However, more definitive characterization of A 1 receptor-mediated effects and elucidation of the possible signaling mechanisms are necessary for the development of potential therapies in the management of vascular disease. A 1 receptor signaling in vascular smooth muscle is less understood, although it is generally agreed that vascular contraction results from calcium mobilization subsequent to activation of the PLC pathway (2) .
Characterization of the A 1 adenosine receptor-mediated vascular response was performed in this study by combining a traditional pharmacological approach with newly available gene-modified animal models. Isolated in vitro preparations of mouse aortic rings were used to study the effects of A 1 adenosine receptors on vascular smooth muscle tone. We hypothesized that adenosine A 1 receptors negatively modulate adenosine-mediated regulation of vascular tone through the PLC pathway. Preparation of isolated aortic rings. While mice were under deep anesthesia with pentobarbital sodium (100 mg/kg ip), a thoracotomy was performed, and the aorta was gently removed. Fat and connective tissue were removed, and the aorta was cut transversely into three or four rings of 3-4 mm in width. The rings were mounted vertically between two stainless steel wire hooks with extreme care being taken to avoid damaging the endothelium. The rings were suspended in 10-ml organ baths that contained Krebs-Henseleit solution continuously gassed with 95% O 2-5% CO2 (37°C, pH 7.4). Aortic rings were allowed to equilibrate for 60 min at an initial resting tension of 1 g, and the bathing solution was changed every 15 min according to our previously described protocol (23) . Composition of the Krebs-Henseleit solution was (in mM) 118 NaCl, 4.8 KCl, 1.2 MgSO 4, 1.2 KH 2PO4, 25 NaHCO3, 2.5 CaCl2, and 11 glucose. Changes in the isometric tension were measured with a fixed-range precision-force transducer (model TSD 125C; BIOPAC Systems) connected to a differential amplifier (model DA 100B; BIOPAC Systems). Data were recorded on a Dell computer using an MP 100 WSW digital acquisition system (BIOPAC Systems) and were analyzed using Acqknowledge 3.5.7 software (BIOPAC Systems) (17) .
MATERIALS AND METHODS

A1
Protocol for agonist dose-response curves. After rings were equilibrated, the responsiveness of each individual ring was checked by successive administration of a submaximally effective concentration of KCl (35 mM). The integrity of the vascular endothelium was tested pharmacologically by acetylcholine-induced relaxation of phenylephrine-precontracted rings. Tissues that did not elicit a reproducible and stable contraction with phenylephrine (1 M) and relaxed Ͻ50% with 0.1 M acetylcholine were discarded from the study. Preparations were then washed several times with Krebs-Henseleit solution and allowed to relax fully for 30 min before the experimental protocol began.
To determine the vasodilator responses to adenosine and adenosine analogs, the aortic rings were precontracted with phenylephrine at a submaximal dose of 1 M (Emax, 10 M). Concentration-response curves (CRCs) for aortic relaxation by agonists were obtained by cumulative addition of agonists to organ baths that contained phenylephrine-precontracted rings. The concentration in the organ bath was increased in 1-log concentration steps. In all cases, agonists were added to yield the next higher concentration only when the response to the earlier dose reached a steady state. One CRC was constructed for each ring. Agonist CRCs were performed in pairs of aortic rings from both A1AR (Ϫ/Ϫ) and A1AR (ϩ/ϩ) mice and were studied in a parallel fashion in the same bath. The adenosine analog 2-chloro-N 6 -cyclopentyladenosine (CCPA) did not cause contraction in nonprecontracted aortic rings from either A1AR (Ϫ/Ϫ) or A1AR (ϩ/ϩ) mice. Pharmacological antagonist protocol. The pharmacological blocking effect of DPCPX (100 nM, selective A1 receptor antagonist) was studied by adding the drug 60 min before contraction of the tissues with phenylephrine; the antagonist was present throughout the experiments. Antagonist experiments were performed in parallel using two rings from the same aorta; one served as a control (without antagonist) and one served as a treatment (with antagonist). The vasodilator (relaxant) or contractile responses are expressed as percent decreases or increases of phenylephrine-induced precontraction. The amount of contraction produced by 1 M phenylephrine in each ring from its initial resting tension (1 g) was considered as 100%.
For the signaling experiments, rings were precontracted with KCl (50 mM) instead of phenylephrine to avoid a possible blocking effect of the PLC inhibitors on phenylephrine-induced vascular smooth muscle contraction. After equilibration for 1 h, CRCs for CCPA (0.1 nM to 100 M) were obtained by cumulative addition to the organ bath after incubation with PLC inhibitors.
The role of the PLC pathway in A1 receptor-mediated contraction of vascular tone was tested in the presence and absence of the PLC inhibitor 1-(6-{[17␤-3-methoxyestra-1,3,5(10)-trien-17-yl]amino}hexyl)-1H-pyrrole-2,5-dione (U-73122, 4 M) for 30 min (2, 5) . A 1AR (ϩ/ϩ) and A 1AR
(Ϫ/Ϫ) mouse aortic rings were incubated with U-73122 before they were contracted with KCl (50 mM), and the CRCs for CCPA were conducted in the presence of the inhibitor. To rule out nonspecific effects of the PLC blocker U-73122, a separate experiment was performed on A 1AR
(ϩ/ϩ) aortic rings using an inactive analog of the PLC inhibitor, 1-(6-{[17␤-3-methoxyestra-1,3,5(10)-trien-17-yl]amino} hexyl)-2,5-pyrrolidine-dione (U-73343), as a control. Experiments were performed in parallel using two rings from the same aorta; one served as a control (without inhibitor) and one served as the treatment (with inhibitor).
Data analysis. Experimental values are presented as means Ϯ SE for each CRC to adenosine receptor agonists. Significant differences in dose response between A 1AR (Ϫ/Ϫ) and A1AR (ϩ/ϩ) groups at individual agonist concentrations were calculated by Student's unpaired t-test. A P value of Ͻ0.05 was considered significant. The concentration required to produce a 50% response (EC 50) in aortic relaxation was obtained by graphic analysis of individual curves by nonlinear regression (curve-fit) analysis.
Chemicals. Phenylephrine and acetylcholine were dissolved in distilled water. CCPA, 5Ј-N-ethyl-carboxamidoadenosine (NECA), 2-(2-carboxyethyl)phenethyl amino-5Ј-N-ethylcarboxamido-adenosine (CGS-21680), 2-chloro-N 6 -3-iodobenzyladenosine-5Ј-N-methyluronamide (Cl-IBMECA), and DPCPX were dissolved in 100% DMSO as 10 mM stock solutions, which were followed by serial dilutions in distilled water. U-73122 and U-73343 were dissolved in DMSO at desired concentrations. We have shown before (23) that DMSO at the concentration used does not alter the response curve. All chemicals were purchased from Sigma Chemical (St. Louis, MO).
RESULTS
Vascular effects of adenosine receptor agonists in isolated aortic rings of A 1 AR
(Ϫ/Ϫ) and A 1 AR (ϩ/ϩ) mice. To examine the possible negative modulatory effects of A 1 receptors on other adenosine receptor subtypes, the nonselective adenosine receptor agonists adenosine and NECA were used. NECA is the only available agonist for A 2B adenosine receptors that predominates adenosine-mediated relaxation in mouse aorta (23) . Adenosine and NECA relaxed phenylephrine-precontracted A 1 AR (Ϫ/Ϫ) and A 1 AR (ϩ/ϩ) aortic rings in a dose-dependent manner. In A 1 AR (Ϫ/Ϫ) aortic rings, the CRC for both adenosine-and NECA-induced relaxation was shifted to the left, which demonstrates an increase in maximal relaxation compared with A 1 AR (ϩ/ϩ) aortic rings ( Figs. 1 and 2 ). The EC 50 values for A 1 AR (Ϫ/Ϫ) aortic relaxation with NECA (1.56 Ϯ 1.7 M) and adenosine (0.14 Ϯ 1.17 M) were lower than those for A 1 AR (ϩ/ϩ) with NECA (8.87 Ϯ 3.7 M) and adenosine (2.98 Ϯ 3.7 M; Figs. 1 and 2) . Also, adenosine and NECA caused contraction of A 1 AR (ϩ/ϩ) aortic rings: 0.1 M adenosine caused a 16.4 Ϯ 6.4% contraction, whereas 0.1 M NECA caused 13.9 Ϯ 3.1% (Figs. 1 and 2 ). These contractile responses were significantly greater than those of A 1 AR (Ϫ/Ϫ) rings, as neither adenosine nor NECA produced any contraction (P Ͻ 0.05). In A 1 AR (ϩ/ϩ) rings, contraction induced by NECA was significantly greater compared with baseline values within the same group (P Ͻ 0.05; Fig. 2) . (ϩ/ϩ) mouse aortic rings (Fig. 8) .
DISCUSSION
The objectives of this study were to determine whether and to what extent A 1 adenosine receptor activation causes negative modulation of adenosine-mediated relaxation of vascular tone. The physiological significance of the coexistence of A 1 receptors with the other adenosine receptor subtypes in the vasculature is still not well understood. An A 1 receptor-mediated increase of vascular tone is not self evident, because another adenosine receptor subtype, the A 3 receptor, elicits the same negative effect on cAMP in the vascular smooth muscle but does not cause vasoconstriction (24) . Nevertheless, activation of A 1 receptors by N 6 -(R-phenylisopropyl)adenosine (R-PIA, a selective A 1 agonist) caused contraction in isolated mouse aortic rings (18) . Also, NECA, a nonselective adenosine receptor agonist, caused contraction in isolated carotid rings from both A 2A receptor-knockout and wild-type mice (19) . Both of these effects of NECA and R-PIA were eliminated by the nonselective adenosine receptor antagonist 8-(p-sulfophenyl)-theophylline and by the selective A 1 receptor antagonist DPCPX (18, 19) . Additional evidence supporting a negative coregulatory role of adenosine A 1 receptors includes the observation that adenosine and N 6 -cyclohexyladenosine (a selective A 1 receptor agonist) caused constriction in perfused afferent arterioles from mouse kidney, and this response was not observed in arterioles from A 1 AR (Ϫ/Ϫ) mice (5). These findings suggest that activation of A 1 adenosine receptors negatively influences the tone of vascular smooth muscle.
However, more definitive characterization of A 1 receptors is necessary to elucidate the function and the impact of these receptors on adenosine-mediated regulation of vascular tone. In the present study, we used aortic rings from mice with targeted deletion of A 1 adenosine receptors in combination with the available selective pharmacological agonists and antagonists for better identification of the role of A 1 receptors in the regulation of vascular smooth muscle tone. Our data demonstrated that adenosine and NECA at a dose of 0.1 M induced small contractions in A 1 AR (ϩ/ϩ) aortic rings (when added after phenylephrine). Most importantly, direct activation of A 1 receptors by CCPA caused significant contraction in A 1 AR (ϩ/ϩ) phenylephrine-precontracted aortic rings at doses of 0.1 and 1.0 M. CCPA is the most potent and selective A 1 adenosine receptor agonist with a K i of 0.8 compared with 2,300 for A 2A , 18,800 for A 2B , and 42 nM for A 3 (11) . The contractile responses caused by adenosine, NECA, or CCPA were not observed in A 1 AR (Ϫ/Ϫ) aortic rings. NECA-and CCPA-induced contractions were completely abolished by 100 nM DPCPX. DPCPX is a highly selective A 1 receptor antagonist with a K i of 3.9 compared with 130 for A 2A , 1,000 for A 2B , and 4,000 nM for A 3 (11) . Taken together, these findings suggest that adenosine-, NECA-, and CCPA-induced contractions of aortic rings were primarily due to activation of A 1 adenosine receptors.
We reported earlier that adenosine-mediated mouse aortic relaxation is predominantly mediated by A 2B receptors, whereas A 2A receptors were suggested to be less important in this vascular bed (23) . In contrast, adenosine-mediated coronary vasodilation is mainly through the activation of A 2A receptors. In human coronary arterioles, Sato et al. (20) reported the presence of adenosine A 1 receptors using 8-cyclopentyl-1,3-dipropylxanthine (an A 1 receptor-selective antagonist), which enhanced coronary relaxation by adenosine. In the same study, the selective A 1 (ϩ/ϩ) aortic rings. This relaxation may be due to the lack of selectivity of this agonist at high doses, which might affect other adenosine receptors that mediate smooth muscle relaxation (possibly A 2B ).
We have also previously shown that adenosine A 1 receptors are involved in the upregulation of PKC in porcine coronary artery (12, 13, 16) . This increase in the expression of PKC was found to occur through an upstream activation of pertussis toxin-sensitive G protein after activation of adenosine A 1 receptors by S-ENBA (12, 13) . Furthermore, in isolated porcine coronary smooth muscle cells, activation of adenosine A 1 receptor with S-ENBA caused upregulation of PKC-␣, -␤ I , -␤ II , -␥, -ε, and -isoforms in a dose-dependent manner (16) . Adenosine A 1 receptor activation has been shown to cause production of inositol 1,4,5-trisphosphate in rabbit airway smooth muscle (2) , which is the possible mechanism behind A 1 receptormediated negative modulation of airway vascular tone.
Recent work by Hansen et al. (5) on perfused mouse kidney afferent arterioles demonstrated a contractile response to N 6 -cyclohexyladenosine (a selective A 1 receptor agonist) in arterioles of A 1 AR (ϩ/ϩ) but not A 1 AR (Ϫ/Ϫ) mice. Pretreatment with pertussis toxin or the PLC inhibitor U-73122 blocked this contractile effect. In our study, U-73122 eliminated CCPAmediated contraction in A 1 AR (ϩ/ϩ) mouse aortic rings and had no effect on CCPA-induced relaxation in both A 1 AR (Ϫ/Ϫ) and A 1 AR (ϩ/ϩ) rings, whereas U-73343 (an inactive analog) did not affect CCPA-mediated contraction in A 1 AR (ϩ/ϩ) rings. These finding suggest that the PLC pathway has a major role in A 1 adenosine receptor-mediated contraction of vascular tone.
In summary, the present study provides the first direct evidence that A 1 adenosine receptors play a negative modulatory role in adenosine-mediated regulation of vascular tone, and this effect is mediated through a PLC signaling pathway.
